Liminal BioSciences Inc.
https://liminalbiosciences.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Liminal BioSciences Inc.
Coronavirus Update: Japan Paxlovid Approval, US Lifts Covaxin IND Hold
Japan has added to its growing arsenal of COVID-19 treatments with the approval of the oral antiviral Paxlovid, while the US FDA has lifted a clinical hold on Bharat's vaccine, which has shown potential against Omicron. Also, Biological E's vaccine is approved for use in adolescents in India
First-In-Class Drugs Made Up More Than Half Of US FDA’s Novel Approvals Last Year
CDER hit a high mark with 27 first-in-class approvals in the 50 novel agents cleared in 2021.
Cerecor Turns The LIGHT Back On As Avalo, With PRV Haul In Sight
The former Cerecor boasts four pipeline assets that could yield US FDA priority review vouchers. Having divested CNS assets, the renamed firm will focus on IBD with first-in-class anti-LIGHT candidate, plus immunology and rare diseases.
Revamped Manufacturing Process Yields Fast-Track Ryplazim Approval Three Years Later
Plasminogen therapy for unmet need licensed after Prometic took the time to develop a manufacturing process it could validate.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
- Large Molecule
- Synthesis Technologies, Production Processes
-
Drug Discovery Tools
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Bioniche Life Sciences Inc.
- Fairhaven Pharmaceuticals Inc.
- Innovon Life Sciences Holdings Limited.
- NantPro BioSciences, LLC
- ProMetic BioTherapeutics
- Prometic ChinaCo
- Prometic Life Sciences Inc.
- Telesta Therapeutics Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice